876P - Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic Renal Cell Carcinoma (mRCC): the Gustave Roussy experience.

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Renal Cell Cancer
Cancer Immunology and Immunotherapy
Genitourinary Cancers
Presenter Lisa Derosa
Citation Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371
Authors L. Derosa1, J.A. Rouche1, E. Colomba1, G. Baciarello1, B. Routy1, L. Albiges2, B. Escudier1
  • 1Medical Oncology, Gustave Roussy, 94800 - Villejuif  /FR
  • 2Medical Oncology, Gustave Roussy, Villejuif  /FR



Optimal treatment sequence in mRCC remains unclear, although PD-1/PD-L1 inhibitors are becoming standard of care in second or third-line. There is little evidence about the efficacy of antiangiogenic therapies after immune checkpoint inhibitors (ICI), especially of C, which was recently approved for mRCC. We report our initial experience of C efficacy after prior ICI.


We conducted a retrospective analysis of mRCC patients (pts) enrolled on clinical trials at Gustave Roussy with ICI with a special focus on C as subsequent therapy. Clinical outcome during C treatment, including Time to Treatment Failure (TTF), Objective Response Rate (ORR), Overall Survival (OS) and safety are reported.


After a median follow-up of 60 months (mo), among 127 pts treated with ICI (n: 107; nivolumab), 44 (35%) were still on-treatment and 5 pts had stable disease after treatment interruption. Among the 78 pts who progressed after ICI, 22 pts (28%) never received further treatment. 56 pts (72%) received further therapies: 18 (32%) C, 25 (44%) Axitinib (A) and 13 (24%) other (O). C was given as third-line or beyond in 27% and 73% of pts, respectively. Before starting C, pts were only intermediate or poor prognosis by IMDC criteria. Considering all evaluable pts, ORR was 33%, median TTF was 7.99 mo and median OS was 12.33 mo. Focusing on C, ORR was 42% and no pts presented progressive disease as best response versus 37% for A with 2% progressive disease. Currently, median TTF and OS on C are not yet estimable (0.92-not reached); update on clinical outcome will be presented. Moreover, C demonstrated acceptable safety profile and the rate of treatment discontinuation because of adverse events was 11%.


In mRCC pts previously treated by ICI, treatment with C seems to be very active, irrespective of number of prior treatments or IMDC risk group. Prior PD-1/PD-L1 exposure did not influence safety of subsequent C therapy. Interestingly, activity of A also appears excellent, raising the hypothesis of enhanced efficacy of TKI after ICI.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Not applicable




B. Escudier: Honorarium received from: Bristol-Myers Squib, Novartis, Pfizer, Ipsen, Roche, Bayer, Calithera, Acceleron, EUSA, Eisai. All other authors have declared no conflicts of interest.